Brief: UCB's Rystiggo Gets EU Approval For Two New Administration Methods
Jan 31 (Reuters) - Ucb SA UCB.BR :
* RYSTIGGO RECEIVES EU APPROVAL FOR TWO NEW ADMINISTRATION
METHODS
* SELF-ADMINISTRATION OF ROZANOLIXIZUMAB IS ALSO BEING
REVIEWED BY
THE JAPANESE PHARMACEUTICALS AND MEDICAL DEVICES AGENCY (PMDA)
Source text: ID:
Further company coverage: UCB.BR
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on UCB SA
See all newsAnalysis: US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
Brief: UCB Announces Data Showing Positive Impact Of Kygevvi In Tk2d Patients
Brief: UCB Completes $2.2 Billion Acquisition Of Candid Therapeutics
Europe Research Roundup: Banca Generali, Ferrari, Prysmian
Barclays downgrades UCB after rally, sees limited upside